A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer

Okamoto, Hiroaki; Naoki, Katsuhiko; Narita, Yusuke; Hida, Naoya; Kunikane, Hiroshi; Watanabe, Kenji

doi:10.1016/j.lungcan.2006.05.004

Cited by 22 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the results of our trial, a phase III trial of the CE regimen vs amrubicin monotherapy, supported by a pharmaceutical company, is now ongoing in elderly patients with ED-SCLC in Japan, and a comparative trial of the CE regimen vs carboplatin plus irinotecan regimen (Okamoto et al, 2006) is being discussed for a future trial in our group.…”

Section: Discussionmentioning

confidence: 99%

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

et al. 2007

View full text Add to dashboard Cite

We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age X70 and performance status 0 -2, or age o70 and PS 3. The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m À2 IV on days 1 -3. The SPE arm received cisplatin 25 mg m À2 IV on days 1 -3 and etoposide 80 mg m À2 IV on days 1 -3. Both regimens were given with granulocyte colony-stimulating factor support in a 21 -28 day cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade 3 -4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P ¼ 0.54). Palliation scores were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk -benefit balance.

show abstract

Section: Discussionmentioning

confidence: 99%

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This may be related to pharmacogenomic differences as well as molecular differences in lung cancer that may exist between North American or European and Japanese patient populations. The combination chemotherapy of irinotecan and carboplatin was also investigated in elderly patients with granulocyte colony-stimulating factor support [20] as well as in patients with refractory or relapsed SCLC [21,22]. In the phase II study of Hirose and colleagues, 22 patients were treated with irinotecan 50 mg/m 2 on days 1 and 8 plus carboplatin AUC 5 on day 1 every 3 weeks.…”

Section: Discussionmentioning

confidence: 99%

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)

et al. 2007

View full text Add to dashboard Cite

“…Within the limitation of our sample size, we observed no statistically significant difference in the treatment outcomes between younger and older patients. In addition, a Japanese study showed a RR of 89% and a median OS of 13.3 month with IC regimen in elderly patients with SCLC (age C70 years), although this study included both ED and limited disease patients [35]. These findings suggest elderly patients could be good candidates for IC chemotherapy.…”

Section: Discussionmentioning

confidence: 82%

Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

et al. 2010

View full text Add to dashboard Cite

This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m(2) on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3-4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3-4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥ 65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥ 65 years of age (P = .738). The median PFS and OS (<65 years vs. ≥ 65 years) were 5.3 vs. 5.6 months (P = .835) and 9.0 vs. 8.7 months (P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age.

show abstract

A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer

Cited by 22 publications

References 24 publications

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)

Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

Contact Info

Product

Resources

About